Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Clinical trial NCT06463665 · RECRUITING

Trial details

NCT number: NCT06463665
Sponsor: Genelux Corporation
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Non-squamous Non-small-cell Lung Cancer Advanced Squamous Non-Small Cell Lung Carcinoma Metastatic Non-squamous Non Small Cell Lung Cancer Metastatic Squamous Non-Small Cell Lung Carcinoma Non-small Cell Lung Cancer Non-small Cell Lung Cancer Stage III Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer Recurrent

Start date: 2024-09-26
Primary completion: 2027-02-01
Enrollment: 142

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.